Literature DB >> 33677675

Late-onset MS is associated with an increased rate of reaching disability milestones.

Mads Albrecht Andersen1, Mathias Due Buron2, Melinda Magyari2.   

Abstract

OBJECTIVE: To describe patient characteristics and assess the risk of disability worsening in patients of different age groups with focus on late-onset multiple sclerosis (LOMS) defined as disease onset after the age of 50 years.
METHODS: The nationwide population-based Danish Multiple Sclerosis Registry served as data source. We described baseline characteristics and analyzed rates of reaching Expanded Disability Status Scale (EDSS) milestones.
RESULTS: We identified 28,232 patients with MS with a known year of clinical onset, of which 2661 had LOMS. The LOMS group had a higher proportion of males and patients with primary progressive disease course, and they were less likely to receive disease-modifying therapy. The initial rate of reaching EDSS milestone 6 after diagnosis was higher in LOMS [hazard ratio (HR) 1.53; 95% confidence interval (CI) 1.14-2.06]; however, when assessing the risk of reaching EDSS 6 according to age, the HR was significantly lower for the LOMS group (HR 0.307; 95% CI 0.221-0.426).
CONCLUSION: The clinical characteristics and treatment approaches for patients with LOMS differ from their younger counterparts. Following diagnosis, patients with LOMS initially have an increased rate of reaching EDSS score 6; however, the risk of reaching EDSS score 6 at any given age is higher in patients with non-LOMS.

Entities:  

Keywords:  Ageing; Disability; Late-onset; Multiple sclerosis; Real-word studies

Year:  2021        PMID: 33677675     DOI: 10.1007/s00415-021-10490-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  19 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale.

Authors:  E L Korn; B I Graubard; D Midthune
Journal:  Am J Epidemiol       Date:  1997-01-01       Impact factor: 4.897

3.  Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.

Authors:  Nils Koch-Henriksen; Bjarne Laursen; Egon Stenager; Melinda Magyari
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08       Impact factor: 10.154

4.  Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.

Authors:  E D'Amico; F Patti; A Zanghì; C G Chisari; S Lo Fermo; M Zappia
Journal:  Eur J Neurol       Date:  2018-08-03       Impact factor: 6.089

Review 5.  Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis.

Authors:  V Martinelli; M Rodegher; L Moiola; G Comi
Journal:  Neurol Sci       Date:  2004-11       Impact factor: 3.307

6.  Late-onset multiple sclerosis.

Authors:  M L Polliack; Y Barak; A Achiron
Journal:  J Am Geriatr Soc       Date:  2001-02       Impact factor: 5.562

7.  Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women.

Authors:  Nils Koch-Henriksen; Lau Caspar Thygesen; Egon Stenager; Bjarne Laursen; Melinda Magyari
Journal:  Neurology       Date:  2018-05-02       Impact factor: 9.910

8.  Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.

Authors:  Maria Pia Amato; Mattia Fonderico; Emilio Portaccio; Luisa Pastò; Lorenzo Razzolini; Elio Prestipino; Angelo Bellinvia; Laura Tudisco; Roberto Fratangelo; Giancarlo Comi; Francesco Patti; Giovanna De Luca; Vincenzo Brescia Morra; Eleonora Cocco; Carlo Pozzilli; Patrizia Sola; Roberto Bergamaschi; Giuseppe Salemi; Matilde Inglese; Enrico Millefiorini; Simonetta Galgani; Mauro Zaffaroni; Angelo Ghezzi; Marco Salvetti; Giacomo Lus; Ciro Florio; Rocco Totaro; Franco Granella; Marika Vianello; Maurizia Gatto; Giancarlo Di Battista; Umberto Aguglia; Francesco Ottavio Logullo; Marta Simone; Giuseppe Lucisano; Pietro Iaffaldano; Maria Trojano
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

9.  Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Authors:  Hanne Marie Bøe Lunde; Jörg Assmus; Kjell-Morten Myhr; Lars Bø; Nina Grytten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-04-01       Impact factor: 10.154

10.  The Danish Multiple Sclerosis Registry.

Authors:  Melinda Magyari; Hanna Joensen; Bjarne Laursen; Nils Koch-Henriksen
Journal:  Brain Behav       Date:  2020-10-30       Impact factor: 2.708

View more
  1 in total

1.  First-line therapies in late-onset multiple sclerosis: An Italian registry study.

Authors:  Aurora Zanghì; Carlo Avolio; Maria Pia Amato; Massimo Filippi; Maria Trojano; Francesco Patti; Emanuele D'Amico
Journal:  Eur J Neurol       Date:  2021-07-30       Impact factor: 6.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.